Corpus ID: 51828117

Oral anticoagulation therapy in the elderly La terapia anticoagulante orale negli anziani

  title={Oral anticoagulation therapy in the elderly La terapia anticoagulante orale negli anziani},
  author={Emilio Attena and A. Ascione and M Borgia and A. Ruocco and Raffaele Sangiuolo},
I pazienti anziani sono a maggior rischio di tromboembolia a causa della presenza di comorbidità, di polifarmacoterapia e dell’invecchiamento. Gli anziani presentano un aumentato rischio sia tromboembolico, arterioso e venoso, che emorragico per tale motivo risulta difficile la scelta della miglior terapia da parte del medico. Negli ultimi anni sono stati creati dei sistemi di punteggio per la valutazione del rischio di stroke e di quello emorragico che potessero aiutare il medico nella scelta… Expand


Efficacy and safety of novel oral anticoagulants for treatment of acute venous thromboembolism: direct and adjusted indirect meta-analysis of randomised controlled trials
Compared with vitamin K antagonists, the novel oral anticoagulants had a similar risk of recurrence of acute venous thromboembolism and all cause mortality, though rivaroxaban was associated with a reduced risk of bleeding. Expand
Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
There is a large amount of evidence on laboratory and clinical characteristics of vitamin K antagonists and a growing body of evidence is becoming available on the first new oral anticoagulant drugs available for clinical use, dabigatran and rivaroxaban. Expand
Efficacy and safety of dabigatran etexilate and warfarin in "real-world" patients with atrial fibrillation: a prospective nationwide cohort study.
In this "everyday clinical practice" post-approval nationwide clinical cohort, there were similar stroke/systemic embolism and major bleeding rates with dabigatran (both doses) compared with warfarin, and Mortality, intracranial bleeding, pulmonary emblism, and MI were lower with dabIGatran, compared withwarfarin. Expand
Abstract 148: Efficacy and Safety of Rivaroxaban Compared with Warfarin Among Elderly Patients with Nonvalvular Atrial Fibrillation in the ROCKET-AF Trial
In elderly, high-risk patients with AF, once-daily oral rivaroxaban without coagulation monitoring or dose adjustment performed favorably compared to adjusted-dose warfarin as it did in the overall ROCKET-AF population. Expand
Use of anticoagulants in elderly patients: practical recommendations
Assessing the benefit-risk ratio of anticoagulation is one of the most challenging issues in the individual elderly patient, patients at highest hemorrhagic risk often being those who would have the greatest benefit from anticoAGulants. Expand
Efficacy and Safety of the Novel Oral Anticoagulants in Atrial Fibrillation: A Systematic Review and Meta-Analysis of the Literature
Novel oral anticoagulants are associated with an overall clinical benefit compared with vitamin K antagonists, and additional research is required to confirm these findings outside the context of randomized trials. Expand
The PLAT Study: hemostatic function in relation to atherothrombotic ischemic events in vascular disease patients. Principal results. PLAT Study Group. Progetto Lombardo Atero-Trombosi (PLAT) Study Group.
The Progetto Lombardo Atero-Trombosi (PLAT) Study was a prospective, multicenter, multidisciplinary study of the association among hemostatic variables, conventional risk factors, andExpand
Multicentre experience with MGuard™ net protective stent in ST‐elevation myocardial infarction: Safety, feasibility, and impact on myocardial reperfusion
  • F. Piscione, G. Danzi, +9 authors M. Chiariello
  • Medicine
  • Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions
  • 2010
MGS might represent a safe and feasible option for PCI in STEMI patients, providing high perfusional and ECG improvement, and further randomized trials comparing this strategy with the conventional one are needed in the near future to assess the impact on clinical practice of this strategy. Expand
Antiplatelet agents versus control or anticoagulation for heart failure in sinus rhythm.
  • G. Lip, C. Gibbs
  • Medicine
  • The Cochrane database of systematic reviews
  • 2001
There is no evidence from long term RCTs to recommend use of aspirin to prevent thromboembolism in patients with heart failure in sinus rhythm and a possible interaction with ACE inhibitors may reduce the efficacy of aspirin. Expand
Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group.
In patients with angina pectoris, the levels of fibrinogen, von Willebrand factor antigen, and t-PA antigen are independent predictors of subsequent acute coronary syndromes and characterize patients at low risk for coronary events despite increased serum cholesterol levels. Expand